PEG-somatropin
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency
Trial Timeline
Jan 1, 2015 → —
NCT ID
NCT03249480About PEG-somatropin
PEG-somatropin is a approved stage product being developed by Sun Pharmaceutical for Growth Hormone Deficiency. The current trial status is unknown. This product is registered under clinical trial identifier NCT03249480. Target conditions include Growth Hormone Deficiency.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03249480 | Approved | UNKNOWN |
| NCT01495468 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85